Moleculin CEO to Present Oncology Pipeline Updates at 2026 Maxim Growth Summit

  • Moleculin Biotech CEO Walter Klemp to present at the 2026 Maxim Growth Summit on October 14, 2026.
  • Focus on Annamycin's Phase 2/3 MIRACLE trial for relapsed/refractory AML, with Part A enrollment completed.
  • Comprehensive Part A data readout expected in Q1 2027.
  • Company to hold one-on-one investor meetings during the event.

Moleculin's presentation comes at a critical juncture for its lead candidate, Annamycin, as it progresses through late-stage clinical trials. The company is positioning itself as a key player in the oncology space, particularly for hard-to-treat tumors like relapsed/refractory AML. The event provides an opportunity to gauge investor interest and assess the company's ability to execute on its clinical and financial goals.

Trial Execution
Whether Moleculin can maintain its timeline for the comprehensive Part A data readout in Q1 2027.
Investor Sentiment
How the market reacts to the presentation and one-on-one investor meetings.
Financing Needs
The company's ability to secure additional financing for its clinical trials.